New obesity drug candidate cagrilintide tested in Head-to-Head trial
NCT ID NCT07597018
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two versions of the experimental drug cagrilintide in 234 adults with overweight or obesity. Participants receive either version D or version B by injection once a week for about 6 months. The goal is to see how the drug is processed in the body, not to measure weight loss directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cagrilintide
What this could lead to
If successful, this study could help determine which version of cagrilintide is better for weight management, potentially leading to a new treatment option for obesity.
What could go wrong
This is an early Phase 1 trial focused on how the drug behaves in the body, not on weight loss or safety. The results may not lead to an approved treatment, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Parexel International GmbH
RECRUITINGBerlin, 14050, Germany